-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Read: On July 30, AstraZeneca released its second-quarter 2020 results.
July 30, AstraZeneca reported second-quarter 2020 results: total revenue of $6.275 billion, up 8% yoY, product sales of $6,048 million, up 6% year-on-year, and core earnings per share (EPS) at $0.96, up 32% year-on-year.
's first-half revenue was $12.629 billion, up 12% YoY, product sales were $12.359 billion, up 11% YoY, and core EPS was $2.01, up 24% YoY.
AstraZeneca's performance remained strong against the backdrop of the GLOBAL PANDEMIC of COVID-19, with revenue, profits and cash flow continuing to grow.
the first half of the year, innovation drugs, the three core areas, each market continued to grow: - Innovative drugs increased significantly: revenues of $6.353 billion, up 42%, of which $1.406 billion in emerging markets, up 71%, these drugs accounted for 50% of global revenue (40% in 2019).
- Three Core Therapeutics Areas: (1) Oncology Revenue of $5.324 billion, up 28%.
(2) Cardiovascular, Kidney and Metabolic Business (CVRM) revenue was $2.265 billion, up 8%.
(3) Revenue from the respiratory and immunology business was $2.676 billion, up 5 percent, with total revenue from the respiratory and immunology business falling 11 percent to $1.122 billion in the second quarter, reflecting the negative impact of COVID-19 on Pulmicort in the Chinese market.
- Growth continued in every market: (1) Emerging market revenues rose 9 per cent to $4.329 bn, with Revenues in China up 10 per cent to $2.659bn, up 7 per cent on second-quarter revenues of $1.243bn.
(2) U.S. market revenue rose 13 percent to $4.177 billion.
(3) European market revenue sharply increased 17% to $2,447 million.
the first half of the year, the cancer target drug Tagrisso ($2,016 million, up 43 percent), the anti-PD-L1 therapy Imfinzi ($954 million, up 51 percent), and the PARP inhibitor Lynparza ($816 million, up 57 percent), and the new drug Calence ($195 million), which was sold in the oncology business, exceeded expectations.
SGLT2 inhibitors Farxiga ($848 million, up 17 percent) and anticoagulant Brilinta ($845 million, up 15 percent), Symbicort ($1.442 billion, up 23 percent) and Fasenra ($426 million, up 44 percent) in CVRM's business.
in pipeline, the company has made further significant progress, highlighted by the overwhelming success of Tagrisso in the treatment of early EGFR mutation sucellular lung cancer Phase III ADAURA trials, and Farxiga's expansion of its therapeutic potential beyond diabetes. in addition,
, the company has strengthened its oncology partnership with First Three, reaching a $6 billion partnership on the new product DS-1062. in addition,
the company is rapidly responding to the outbreak and is now able to deliver more than 2 billion doses of the vaccine product AZD122, while accelerating the development of monoclonal antibody therapy and accelerating new clinical trials in patients affected by COVID-19.
the company's 2020 financial guidance remains unchanged and total revenue is expected to grow by double-digit percentages in the high single digits to the lowest.
Core EPS is expected to grow by a median-to-to-to-high double-digit percentage.
the risks and uncertainties associated with the impact of the outbreak, the company expects the quarterly results to continue to change.
.